Genzyme (GENZ) Expects FDA Approval For Myozyme By End of Year
More News related to GENZ
- Notable Analyst Rating Changes 9/5: UL, MON, NAV, HOS Upgraded; ANF, TJX, AMD, NBR Downgraded
- Merrill Lynch Resumes Coverage on Genzyme (GENZ) with a Buy
- BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
- Genzyme (GENZ) and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics
- Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
Genzyme (Nasdaq: GENZ) expects FDA approval by the end of this year for alglucosidase alfa (Myozyme(R)) produced at the 2000L bioreactor scale, following the submission of a BLA on May 30. European approval of Myozyme produced at the 4000L scale is expected in the first half of next year.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+1.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
